{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:26:00Z","timestamp":1793895960563,"version":"4.8.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014337","name":"A Menarini Pharmaceutical Industries Riunite","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011319","name":"Skin Treatment and Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031645","name":"Novartis Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018589","name":"Heart Care Foundation of India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018589","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijcard.2026.134646","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:31:20Z","timestamp":1782491480000},"page":"134646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease"],"prefix":"10.1016","volume":"461","author":[{"given":"Aldo P.","family":"Maggioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Orso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Lucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2026.134646_bb0005","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134646_bb0010","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"ESC scientific document group. 2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134646_bb0015","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/eurheartj\/ehaf174","article-title":"Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis","volume":"46","author":"Samuel","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134646_bb0020","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"LoDoCo2 trial investigators. Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134646_bb0025","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"SELECT trial investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134646_bb0030","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"SOUL study group. Oral Semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134646_bb0035","first-page":"457","article-title":"a nome dei Ricercatori dello Studio BRING-UP Prevenzione. Studio BRING-UP Prevenzione: un modello di partecipazione nazionale volto al miglioramento delle strategie di prevenzione secondaria","volume":"26","author":"Colivicchi","year":"2025","journal-title":"G Ital Cardiol (Rome)"},{"key":"10.1016\/j.ijcard.2026.134646_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/2047487317740663","article-title":"Current management and treatment of patients with stable coronary artery diseases presenting to cardiologists in different clinical contexts: a prospective, observational, nationwide study","volume":"25","author":"De Luca","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134646_bb0045","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"ESC scientific document group. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134646_bb0050","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1)","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ijcard.2026.134646_bb0055","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/dom.13396","article-title":"Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme","volume":"20","author":"JH","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ijcard.2026.134646_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2026.134646_bb0065","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1007\/s12325-021-01637-6","article-title":"Efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus: a network meta-analysis","volume":"38","author":"Jiang","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ijcard.2026.134646_bb0070","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ijcard.2026.134646_bb0075","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/dom.14997","article-title":"Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ijcard.2026.134646_bb0080","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2026.134646_bb0085","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"Herrington","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134646_bb0090","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134646_bb0095","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"STEP 1 study group. Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134646_bb0100","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"STEP 2 study group. semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2026.134646_bb0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"FLOW trial committees and investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134646_bb0110","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"STEP-HFpEF trial committees and investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134646_bb0115","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2026.134646_bb0120","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134646_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133028","article-title":"Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome","volume":"423","author":"De Sio","year":"2025","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134646_bb0130","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.hlc.2025.01.011","article-title":"Eligibility for Semaglutide 2.4 mg in patients with acute myocardial infarction and overweight or obesity without diabetes: a real-world analysis","volume":"34","author":"Ajmera","year":"2025","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.ijcard.2026.134646_bb0135","unstructured":"Emulation of the SOUL Diabetes Trial in Healthcare Claims (ClinicalTrials.gov ID NCT06659718), https:\/\/clinicaltrials.gov\/study\/NCT06659718, 2026 (accessed 26 June 2026)."},{"key":"10.1016\/j.ijcard.2026.134646_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ph18060856","article-title":"Real-world analysis of short-term effectiveness of oral semaglutide: impact on glycometabolic control and cardiovascular risk","volume":"18","author":"Palazzi","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ijcard.2026.134646_bb0145","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1111\/dom.16370","article-title":"Population-level impact of semaglutide 2.4mg in patients with obesity or overweight and cardiovascular disease: a modelling study based on the SELECT trial","volume":"27","author":"Nanna","year":"2025","journal-title":"Diabetes Obes. Metab."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326004961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326004961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:46:28Z","timestamp":1793893588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527326004961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"alternative-id":["S0167527326004961"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134646","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"134646"}}